Advertisement

Topics

Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases

16:23 EDT 29 Jun 2017 | Biotech-Finances

Thursday, June 29th 2017 at 8:05pm UTC Gene Therapy Leader Advancing Pipeline of Programs for Inherited Retinal Diseases, Including Upcoming Phase 3 Trial for Choroideremia BOSTON & LONDON–(BUSINESS WIRE)– NightstaRx Limited (“Nightstar”), a late-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, today announced the completion of a $45 million Series C financing transaction. …

Cet article Nightstar Raises $45 Million to Fund Development of Gene Therapies
for Blinding Retinal Diseases
est apparu en premier sur EEI-BIOTECHFINANCES.

Original Article: Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases

NEXT ARTICLE

More From BioPortfolio on "Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...